The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Do all patients with primary retroperitoneal sarcoma benefit from resection?
 
Carol Swallow
No Relationships to Disclose
 
Sara Iadecola
No Relationships to Disclose
 
Juliana Restrepo-Lopez
No Relationships to Disclose
 
Deanna Ng
No Relationships to Disclose
 
Francesco Barretta
No Relationships to Disclose
 
Silva Ljevar
No Relationships to Disclose
 
Costanza Figura
No Relationships to Disclose
 
Wendy Johnston
No Relationships to Disclose
 
Marco Fiore
No Relationships to Disclose
 
Carlo Morosi
No Relationships to Disclose
 
Elena DiBlasi
No Relationships to Disclose
 
Giovanna Roberta Sanfilippo
Consulting or Advisory Role - Boehringer Ingelheim; RAIN (Inst)
Research Funding - Advenchen Laboratories (Inst); Amgen/Dompé (Inst); AORG Pharmaceuticals (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Daiichi-Sankyo (Inst); Deciphera (Inst); Eisai (Inst); Epizyme (Inst); Foghorn Therapeutics (Inst); GlaxoSmithKline (Inst); Hutchison MediPharma (Inst); InhibRx (Inst); Karyopharm Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); PTC Therapeutics (Inst); RAIN (Inst); SpringWorks Therapeutics (Inst)
Travel, Accommodations, Expenses - PharmaMar
 
Chiara Fabbroni
No Relationships to Disclose
 
Silvia Stacchiotti
Honoraria - Boehringer Ingelheim; Gentili; GlaxoSmithKline; PharmaMar; Servier
Consulting or Advisory Role - Agenus; Bayer; Boehringer Ingelheim; Daiichi Sankyo; deciphera; GlaxoSmithKline; Ikena Oncology; Ipsen; NEC OncoImmunity AS; Pharmaessentia; Regeneron; SERVIER
Research Funding - Abbisko Therapeutics (Inst); Advenchen Laboratories (Inst); Amgen (Inst); Ayala Pharmaceuticals (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Epizyme (Inst); GlaxoSmithKline (Inst); Hutchison MediPharma (Inst); InhibRx (Inst); Karyopharm Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Rain Therapeutics (Inst); SpringWorks Therapeutics (Inst)
Travel, Accommodations, Expenses - PharmaMar
 
Rosalba Miceli
Honoraria - Boehringer Ingelheim
 
Rebecca Gladdy
No Relationships to Disclose
 
Savtaj Brar
No Relationships to Disclose
 
Dario Callegaro
Consulting or Advisory Role - Boehringer Ingelheim
Patents, Royalties, Other Intellectual Property - 'FIRMA PROGNOSTICA PER SOGGETTI AFFETTI DA SARCOMI RETROPERITONEALI' Italian patent number 102024000004447 from Feb 29th, 2024. This is a prognostic transcriptomic signature for patients with retroperitoneal sarcoma.
 
Sandro Pasquali
Research Funding - Astex Pharmaceuticals (Inst); Ikena Oncology (Inst)
 
Alessandro Gronchi
Honoraria - Deciphera; Lilly; Novartis; Pfizer; PharmaMar
Consulting or Advisory Role - Boehringer Ingelheim; Spring Works Therapeutics
Research Funding - Nanobiotix (Inst); PharmaMar (Inst)
Travel, Accommodations, Expenses - Nanobiotix; PharmaMar